Topline-Results indicate the Success of the two Phase-3-ALXN1210 Clinical Trials in Complement Inhibitor Treatment-Naive Patients with paroxysmal nocturnal Hemoglobinuria (PNH) and those previously treated with Soliris (R) (Eculizumab)-MedSci.cn

Topline-Results indicate the Success of the two Phase-3-ALXN1210 Clinical Trials in Complement Inhibitor Treatment-Naive Patients with paroxysmal nocturnal Hemoglobinuria (PNH) and those previously treated with Soliris (R) (Eculizumab)

[Anonymous]

TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018; 45 (4):

科室
- - 订阅+
  - 更多科室
工具
服务